Regeneron Pharmaceuticals (REGN) Retained Earnings (2009 - 2026)

Regeneron Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 59.11% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $11.9 million, a 59.11% decrease from a year earlier, with the FY2025 full-year figure at $35.8 billion, up 178.45% from the prior year.
• Retained Earnings eased to $11.9 million in Q1 2026 per REGN's latest filing, from $35.8 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $35.8 billion in Q4 2025 and bottomed at -$275.1 million in Q3 2022.
• The 5-year median for Retained Earnings is $11.9 billion (2024), against an average of $11.9 billion.
• Across the five-year window, Retained Earnings soared 122997.53% in 2022 and slumped 102.17% in 2023, its largest moves.
• Year by year, Retained Earnings stood at $23.3 billion in 2022, then advanced by 16.96% to $27.3 billion in 2023, then tumbled by 52.84% to $12.9 billion in 2024, then soared by 178.45% to $35.8 billion in 2025, then slumped by 99.97% to $11.9 million in 2026.
• Per Business Quant, the three latest REGN Retained Earnings figures stand at $11.9 million (Q1 2026), $35.8 billion (Q4 2025), and $69.0 million (Q3 2025).